PBH Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 21.02% compared to Prestige Consumer Healthcare's net margin of 32.59%. Prestige Consumer Healthcare's return on equity of 12.65% beat Eli Lilly and's return on equity of 80.24%.

Prestige Consumer Healthcare has a consensus price target of $86.67, signalling upside risk potential of 6.39%. On the other hand Eli Lilly and has an analysts' consensus of $1,011.63 which suggests that it could grow by 39.78%. Given that Eli Lilly and has higher upside potential than Prestige Consumer Healthcare, analysts believe Eli Lilly and is more attractive than Prestige Consumer Healthcare.

Prestige Consumer Healthcare has a beta of 0.470, which suggesting that the stock is 53.023% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Prestige Consumer Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.75% to investors and pays a quarterly dividend of $1.50 per share. Prestige Consumer Healthcare pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Prestige Consumer Healthcare quarterly revenues are $290.3M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Prestige Consumer Healthcare's net income of $61M is lower than Eli Lilly and's net income of $4.4B. Notably, Prestige Consumer Healthcare's price-to-earnings ratio is 19.08x while Eli Lilly and's PE ratio is 61.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare is 3.65x versus 14.53x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 21.02% compared to Prestige Consumer Healthcare's net margin of -49.65%. Prestige Consumer Healthcare's return on equity of 12.65% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Prestige Consumer Healthcare has a consensus price target of $86.67, signalling upside risk potential of 6.39%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 72.76%. Given that NovaBay Pharmaceuticals has higher upside potential than Prestige Consumer Healthcare, analysts believe NovaBay Pharmaceuticals is more attractive than Prestige Consumer Healthcare.

Prestige Consumer Healthcare has a beta of 0.470, which suggesting that the stock is 53.023% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Prestige Consumer Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare quarterly revenues are $290.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Prestige Consumer Healthcare's net income of $61M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Prestige Consumer Healthcare's price-to-earnings ratio is 19.08x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare is 3.65x versus 0.05x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 21.02% compared to Prestige Consumer Healthcare's net margin of -2357.27%. Prestige Consumer Healthcare's return on equity of 12.65% beat Palatin Technologies's return on equity of --.

Prestige Consumer Healthcare has a consensus price target of $86.67, signalling upside risk potential of 6.39%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1479.78%. Given that Palatin Technologies has higher upside potential than Prestige Consumer Healthcare, analysts believe Palatin Technologies is more attractive than Prestige Consumer Healthcare.

Prestige Consumer Healthcare has a beta of 0.470, which suggesting that the stock is 53.023% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Prestige Consumer Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare quarterly revenues are $290.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Prestige Consumer Healthcare's net income of $61M is higher than Palatin Technologies's net income of -$2.4M. Notably, Prestige Consumer Healthcare's price-to-earnings ratio is 19.08x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare is 3.65x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

X4 Pharmaceuticals has a net margin of 21.02% compared to Prestige Consumer Healthcare's net margin of -2776.92%. Prestige Consumer Healthcare's return on equity of 12.65% beat X4 Pharmaceuticals's return on equity of -82%.

Prestige Consumer Healthcare has a consensus price target of $86.67, signalling upside risk potential of 6.39%. On the other hand X4 Pharmaceuticals has an analysts' consensus of $2.79 which suggests that it could grow by 1157.27%. Given that X4 Pharmaceuticals has higher upside potential than Prestige Consumer Healthcare, analysts believe X4 Pharmaceuticals is more attractive than Prestige Consumer Healthcare.

Prestige Consumer Healthcare has a beta of 0.470, which suggesting that the stock is 53.023% less volatile than S&P 500. In comparison X4 Pharmaceuticals has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.116%.

Prestige Consumer Healthcare has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. X4 Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare pays -- of its earnings as a dividend. X4 Pharmaceuticals pays out -- of its earnings as a dividend.

Prestige Consumer Healthcare quarterly revenues are $290.3M, which are larger than X4 Pharmaceuticals quarterly revenues of $1.4M. Prestige Consumer Healthcare's net income of $61M is higher than X4 Pharmaceuticals's net income of -$39.8M. Notably, Prestige Consumer Healthcare's price-to-earnings ratio is 19.08x while X4 Pharmaceuticals's PE ratio is 7.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare is 3.65x versus -- for X4 Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.